Jump to: navigation, search

WikiDoc Resources for Lincosamides


Most recent articles on Lincosamides

Most cited articles on Lincosamides

Review articles on Lincosamides

Articles on Lincosamides in N Eng J Med, Lancet, BMJ


Powerpoint slides on Lincosamides

Images of Lincosamides

Photos of Lincosamides

Podcasts & MP3s on Lincosamides

Videos on Lincosamides

Evidence Based Medicine

Cochrane Collaboration on Lincosamides

Bandolier on Lincosamides

TRIP on Lincosamides

Clinical Trials

Ongoing Trials on Lincosamides at Clinical

Trial results on Lincosamides

Clinical Trials on Lincosamides at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lincosamides

NICE Guidance on Lincosamides


FDA on Lincosamides

CDC on Lincosamides


Books on Lincosamides


Lincosamides in the news

Be alerted to news on Lincosamides

News trends on Lincosamides


Blogs on Lincosamides


Definitions of Lincosamides

Patient Resources / Community

Patient resources on Lincosamides

Discussion groups on Lincosamides

Patient Handouts on Lincosamides

Directions to Hospitals Treating Lincosamides

Risk calculators and risk factors for Lincosamides

Healthcare Provider Resources

Symptoms of Lincosamides

Causes & Risk Factors for Lincosamides

Diagnostic studies for Lincosamides

Treatment of Lincosamides

Continuing Medical Education (CME)

CME Programs on Lincosamides


Lincosamides en Espanol

Lincosamides en Francais


Lincosamides in the Marketplace

Patents on Lincosamides

Experimental / Informatics

List of terms related to Lincosamides

File:Clindamycin skeletal.svg Lincosamides (eg. lincomycin, clindamycin) are a class of drugs which bind to the 23s portion of the 50S subunit of bacterial ribosomes and inhibit early elongation of peptide chain by inhibiting transpeptidase reaction. In this sense they have a similar action to macrolides.

History and uses

The first lincosamide to be discovered was lincomycin, which is a true antibiotic (one occurring naturally rather than being synthetic), from "Streptomyces lincolnensis".

Lincomycin has been superseeded by clindamycin, which exhibits improved antibacterial activity. Clindamycin also exhibits some activity against parasitic protozoa, and has been used in toxoplasmosis and malaria.

They are normally used to treat staphylococci and streptococci, and have proved useful in treating Bacteroides fragili and some other anaerobes.


Target bacteria may alter the drug's binding site (similar to resistance found in macrolides and streptogramins). The resistance mechanism is methylation of the 23s binding site. If this occurs then the bacteria are resistant to both the macrolides and the lincosamides. Also, enzymatic inactivation of clindamycin has been described (rare).


The lincosamides, as the hydrochloride salt, are bitter to taste, so for oral formulation they are given as the palmitate esters, or formulated in capsules. Clindamycin is given intravenously as clindamycin phosphate, which is then converted into active clindamycin wihin the body.


These are bacteriostatic drugs and antagonists of macrolides and streptogramins.

Further reading

  • Van Bambeke F. Mechanisms of action. In Armstrong D, Cohen J. Infectious diseases. Mosby, London, 1999, pp7/1.1-7/1.14